Revance Therapeutics (RVNC) Expected to Announce Quarterly Earnings on Wednesday

Revance Therapeutics (NASDAQ:RVNC) is expected to post its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Revance Therapeutics to post earnings of ($0.29) per share and revenue of $78.12 million for the quarter.

Revance Therapeutics Price Performance

RVNC opened at $3.65 on Wednesday. The stock has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90. The business has a fifty day moving average price of $3.37 and a 200 day moving average price of $4.58. Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $7.56.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Barclays cut their target price on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Monday, December 23rd. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Mizuho decreased their price objective on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research report on Tuesday, December 10th. HC Wainwright reissued a “neutral” rating and issued a $6.60 target price on shares of Revance Therapeutics in a report on Friday, November 8th. Finally, StockNews.com assumed coverage on Revance Therapeutics in a report on Friday, February 14th. They set a “hold” rating for the company. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $8.39.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.